Don't wait lose weight with NutriSystem pasta
Showing posts with label breast cancer. Show all posts
Showing posts with label breast cancer. Show all posts

Wednesday, October 21, 2009

American Cancer Society Stands by its Screening Guidelines; Women Encouraged to Continue Getting Mammograms

/PRNewswire/ -- "Today's New York Times article 'In Shift, Cancer Society Has Concerns on Screening' indicates that the American Cancer Society is changing its guidance on cancer screening to emphasize the risk of overtreatment from screening for breast, prostate, and other cancers.

"While the advantages of screening for some cancers have been overstated, there are advantages, especially in the case of breast, colon and cervical cancers. Mammography is effective - mammograms work and women should continue get them. Seven clinical trials tell us that screening with mammography and clinical breast exam do reduce risk of breast cancer death. This test is beneficial in that it saves lives, but it is not perfect. It can miss cancers that need treatment, and in some cases finds disease that does not need treatment. Understanding these limitations will help researchers develop better screening tests. The American Cancer Society stands by its recommendation that women age 40 and over should receive annual mammography, and women at high risk should talk with their doctors about when screening should begin based on their family history.

"The bottom line is that mammography has helped avert deaths from breast cancer, and we can make more progress against the disease if more women age 40 and older get an annual mammogram.

"Since 1997 the American Cancer Society has recommended that men talk to their doctor and make an informed decision about whether or not prostate cancer early detection testing is right for them. This recommendation also still stands.

"Cancer is a very complex and complicated disease. The American Cancer Society makes evidence-based cancer screening recommendations, and strives to provide clear messages about cancer screening to patients and doctors. Our guidelines are constantly under review to evaluate them as new evidence becomes available. Simple messages are not always possible, and over-simplifying them can in fact do a disservice to the very people we serve."

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
www.artsacrossgeorgia.com
Arts Across Georgia

Tuesday, September 01, 2009

New Call Center Helps Ovarian Cancer Patients Cope With Challenges of Diagnosis

/PRNewswire/ -- Women with ovarian cancer can now find immediate assistance to better cope with their diagnosis by calling 877-OV-HOPE-1 (877-684-6731), a new, free telephone counseling and referral service launched today by a unique partnership: L'Oreal Paris and its charitable partner, the Ovarian Cancer Research Fund (OCRF), and CancerCare, a national non-profit which provides free counseling and education services to individuals and families affected by cancer.

"Any cancer diagnosis is a frightening and stressful experience that can be difficult to cope with," noted Rosalie Canosa, director of program services for CancerCare. "When the diagnosis is ovarian cancer, too many women have no place to turn for help with the emotional and practical impact of their situation."

Ovarian cancer is the eighth most common cancer among U.S. women. This year, approximately 22,000 women will be diagnosed, and nearly 15,000 will lose their lives to the disease, according to the National Cancer Institute. While five-year survival rates exceed 90 percent in early-stage diagnoses, there is no effective early-stage test for the disease, which often is not diagnosed until it reaches an advanced stage, when it is far more difficult to treat successfully.

"Now, with the L'Oreal Paris OCRF Hope Line, women facing ovarian cancer can have their questions answered and find the resources they require to ensure they receive the best care possible," said Canosa.

"We at L'Oreal Paris are deeply committed to providing tangible hope for women battling ovarian cancer," said Karen T. Fondu, president of the L'Oreal Paris Division of L'Oreal USA, Inc. "With the L'Oreal Paris OCRF Hope Line, we hope to continue to work to improve the five-year survival rate for women and provide support along the way."

"OCRF and our dedicated corporate partner, L'Oreal Paris, have been working together for over 12 years to empower women, and to give them hope when they face a diagnosis of ovarian cancer," said Elizabeth Howard, CEO of OCRF. "By joining forces with CancerCare and creating the call center, we are all better able to help women across the United States."

L'Oreal Paris and OCRF generously funded the Hope Line, which is staffed by CancerCare's professional oncology social workers. The Hope Line operates Monday through Friday, 9 a.m. to 5 p.m. Eastern Time.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Thursday, March 26, 2009

Breast Cancer Survivor's Network Open House March 26

The Breast Cancer Survivor's Network will host an open house on Thursday, March 26 at 21 Eastbrook End, Ste 223, in Peachtree City.

Drop in from 2 pm to 6 pm. A library dedication will take place at 2:30 pm.

-----
www.fayettefrontpage.com
Fayette Front Page
Community News You Can Use
Fayetteville, Peachtree City, Tyrone
www.georgiafrontpage.com
Georgia Front Page

Monday, March 23, 2009

Treatment Option In Metastatic Breast Cancer

(NAPSI)-Breast cancer is the second leading cause of cancer deaths in women in the United States. Metastatic breast cancer is the most advanced stage of breast cancer.

For more than 60 years, chemotherapy has been, and continues to be, one of the foundations in the treatment of cancer. Most breast cancer patients will receive chemotherapy at some time during the course of their disease. However, resistance to chemotherapy is a major cause of treatment failure in patients with metastatic breast cancer. Drug resistance is associated with >90 percent of treatment failures in patients with metastatic breast cancer.

In October 2007, the U.S. Food and Drug Administration (FDA) granted approval of the first epothilone chemotherapy, IXEMPRA™ (ixabepilone), as a monotherapy for the treatment of patients with metastatic or locally advanced breast cancer resistant or refractory to anthracyclines, taxanes, and capecitabine. Anthracycline resistance is defined as progression while on therapy or within six months in the adjuvant setting or three months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or four months in the metastatic setting. IXEMPRA was also granted approval in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated.

Your healthcare provider should do blood tests to check your liver function before receiving IXEMPRA and as needed while receiving IXEMPRA. If blood tests show that you have liver problems, do not receive injections of IXEMPRA along with the medicine capecitabine. With liver problems, taking these medicines together could increase your chance of serious infection and death due to a very low white blood cell count (neutropenia).

The most common side effects with IXEMPRA used alone or with capecitabine may include: tiredness; loss of appetite; disorders of toenails and fingernails; hair loss; fever; decreased red blood cells (anemia); joint and muscle pain; headache; decreased platelets (thrombocytopenia); nausea, vomiting, diarrhea, constipation, and abdominal pain; sores on the lip, in the mouth and esophagus; tender, red palms and soles of feet (hand-foot syndrome) that look like a sunburn, the skin may become dry and peel or feel numb and tingle.

"Previously, patients with aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies had limited treatment options," said Linda Vahdat, M.D., Associate Professor of Clinical Medicine, Director Breast Cancer Research Program, Weill Cornell Medical Center. "The approval of IXEMPRA means that we have an important option for patients with metastatic breast cancer who have rapidly progressed through currently approved chemotherapies."

"

Important Safety Information

Indications and Usage:

IXEMPRA™ (ixabepilone) is a prescription medicine used to treat breast cancer, when certain other medicines have not worked or no longer work. IXEMPRA is used alone or with another cancer medicine called capecitabine.

Important Safety Information about IXEMPRA

Your healthcare provider should do blood tests to check your liver function before receiving IXEMPRA and as needed while receiving IXEMPRA. If blood tests show that you have liver problems, do not receive injections of IXEMPRA along with the medicine capecitabine. With liver problems, taking these medicines together could increase your chance of serious infection and death due to a very low white blood cell count (neutropenia).

You should not receive IXEMPRA (ixabepilone), if you are:

• Allergic to a medicine that contains Cremophor® EL1 or polyoxyethylated castor oil.

• Have low white blood cell or platelet counts.

Before you receive treatment with IXEMPRA, a medicine given by injection directly into your vein (intravenous infusion), you should tell your healthcare provider about all your medical conditions, including if you:

• Have liver problems.

• Have heart problems or a history of heart problems.

• Have had an allergic reaction to IXEMPRA. To lower the chance of an allergic reaction, you will receive other medicines about 1 hour before each dose of IXEMPRA.

• Are pregnant or plan to become pregnant. IXEMPRA may harm your unborn baby.

• Are breast-feeding. It is not known if IXEMPRA passes into breast milk.

• Take any medicines, including prescription and non-prescription medicines, vitamins and herbal supplements, including St. John's Wort. IXEMPRA and certain other medicines may affect each other causing side effects.

• Have diabetes.

• Have had numbness, tingling, or burning in the hands or feet (neuropathy)

Things to avoid while taking IXEMPRA:

• IXEMPRA contains alcohol and may cause dizziness or drowsiness. Avoid activities that may be dangerous, such as driving or operating machinery.

• Do not drink grapefruit juice because it may cause you to have too much IXEMPRA in your blood which can lead to side effects.

IXEMPRA may cause serious side effects. Tell your healthcare provider if you have the following:

• Numbness, tingling, or burning in the hands or feet (neuropathy). These symptoms may be new or get worse and often occur early during treatment. Your dose of IXEMPRA may need to be

decreased, stopped until your symptoms get better, or totally stopped.

• White blood cells help protect the body from infections caused by bacteria. If you get a fever or infection when your white blood cells are very low, you can become seriously ill and die. Symptoms

may include, fever (temperature over 100.5), chills, cough, burning, or pain when you urinate. You may need treatment in the hospital with antibiotic medicines.

• Severe allergic reactions can occur and in rare cases cause death. Allergic reactions are most likely to occur when IXEMPRA is being injected. You may experience itching, hives, rash, flushed

face, sudden swelling of face, throat or tongue, chest tightness, trouble breathing, feel dizzy or faint, feel your heart beating (palpitations).

• Chest pain, difficulty breathing, palpitations, or unusual weight gain can be caused by decreased blood flow to the heart, problems with heart function and abnormal heart beat.

The most common side effects with IXEMPRA used alone or with capecitabine may include: tiredness; loss of appetite; disorders of toenails and fingernails; hair loss; fever; decreased red blood cells

(anemia); joint and muscle pain; headache; decreased platelets (thrombocytopenia); nausea, vomiting, diarrhea, constipation, and abdominal pain; sores on the lip, in the mouth and esophagus; ten

der, red palms and soles of feet (hand-foot syndrome) that look like a sunburn, the skin may become dry and peel or feel numb and tingle.

If you have any questions about your health or medicines, talk to your healthcare provider.

Please see accompanying full prescribing information including boxed WARNING regarding liver disease.

1Cremophor is a registered trademark of BASF AG.

Brought to you by Bristol-Myers Squibb.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Sunday, October 05, 2008

Get The Facts About Your Risk For Women's Cancers

(NAPSI)-New findings of an independent survey conducted by Woman's Day magazine showed that too few women know their risk for women's cancers has sparked a call to action for women to learn about reducing cancer risks.

"What You Do Matters" is a call to action from sanofi-aventis to urge women to get the facts about cancer, share their feelings and experiences and prepare for the future learning about how to lower their cancer risks today.

Beyond Breast Cancer

"What You Do Matters" aims to inspire women to learn all they can about early detection, prevention and treatment of women's cancers. In addition to breast cancer, five other types of cancers affecting primarily women are ovarian, uterine, cervical, vulva, and vaginal. In 2008, it is estimated that 260,950 women will be diagnosed with one of these cancers. Just this year, it is estimated that 40,000 American women will die of breast cancer alone.

Olympian Shawn Johnson Speaks Out

"What You Do Matters" speaks to the importance for all women, regardless of age, to get the facts about their risks for cancer.

The company is joined in this effort by Shawn Johnson, 2008 Olympic Champion and a spokesperson for "What You Do Matters." "This cause means a lot to me and my family because when my grandma battled breast cancer 11 years ago, I believe "what we did mattered" to help her get through it," said Shawn. My grandmother and my parents asked a million questions to help her make choices about treatment. She came to live with us, and I did whatever a little girl could to help out. Now as a young adult, I feel I can help make a difference by urging women of all ages to get the facts on their personal cancer history, share their concerns with their doctors and act now to prepare for the future. Because what you do now really does matter."

Survey Results Surprising

In 2008, it is estimated that 260,950 women will be diagnosed, and an estimated 68,970 will die from one of the cancers affecting primarily women. Yet, a recent independent survey conducted by Woman's Day magazine of 7,361 women readers found that too few women have all the information they need about women's cancers. Only one out of two women talked to their doctor about cancer risks. Yet, half of respondents wished they knew where to find credible and reliable information about cancer, and just one fifth feel very knowledgeable about risk factors for women's cancers. The six cancers affecting mostly women are breast, ovarian, uterine, cervical, vulvar and vaginal.

Dedicated to making a difference in the lives of cancer patients and their families, sanofi-aventis urges women to get the facts, share the feelings and look to the future. To learn more about women's cancer risk, visit www.cancerinfo.net. For details on the Woman's Day survey, visit womansday.com.

-----
www.fayettefrontpage.com
Fayette Front Page
Community News You Can Use
Fayetteville, Peachtree City, Tyrone
www.georgiafrontpage.com
Georgia Front Page
www.artsacrossgeorgia.com
Arts Across Georgia

Thursday, October 02, 2008

Facing Women's No.1 Health Fear

(NAPSI)-A recent survey found that breast cancer is the disease women worry about most, more than heart attack, diabetes or lung cancer. The survey also showed that women who are unhappy with their physical appearance are less likely to get lifesaving preventive screenings such as mammograms.

"Our new breast cancer campaign entitled 'Learn. Love. Commit.' seeks to not only give women the information they need on breast cancer risk factors, screening and treatment, but also encourages them to feel self-confident and worthy enough to take preventive steps to keep themselves healthy," said Elizabeth Battaglino Cahill, RN, executive director of the National Women's Health Resource Center (NWHRC), the nonprofit organization for which the study was conducted.

Another interesting finding of the survey is that many women do not realize that age is the biggest risk factor for breast cancer. In the survey, NWHRC discovered that 64 percent of the women incorrectly believed that family history is the single greatest risk factor. This was true regardless of the respondent's age.

On a positive note, 74 percent of respondents report having had a mammogram in the last year, and 61 percent state they have performed a breast self-exam in the last month.

A key factor for women not having a mammogram was cost. Twenty-one percent say they can not afford to get a mammogram.

"With screening technologies becoming more accurate and advanced, coupled with the number of local programs offering free mammograms, women need to know these options are available in their communities," said Lydia Komarnicky, M.D., chair of the Department of Radiation Oncology at Drexel University College of Medicine and medical adviser for the NWHRC's "Learn.Love.Commit." campaign. "We need to make access to mammography as simple and cost effective as possible."

To empower women with the latest information and the confidence to translate that knowledge into action, the National Women's Health Resource Center has launched a new Breast Health Center on its award-winning Web site, www.healthywomen.org.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Tuesday, September 30, 2008

On the Move With a New Breast Cancer Resource

(ARA) – When a woman is first diagnosed with breast cancer, all kinds of questions go through her mind, and not all of them are about the cancer itself. “Will I be able to remain active? What kind of impact will treatment have on my lifestyle? Can I still be intimate with my significant other?”

When California resident Mary Jean Lynberg was first diagnosed with HER2-positive breast cancer back in 2004, she felt numb and physically ill. “My doctor had informed me that the type of tumor I had was fast growing and as a result, she would be very aggressive with my treatment. She told me that meant several rounds of chemotherapy, radiation and maybe even surgery. I was very aware that life as I knew it was going to go through some drastic changes,” Lynberg says.

According to the American Cancer Society, 40,000 women (25 to 30 percent of women with breast cancer) are diagnosed with HER2-positive breast cancer every year. HER2 is part of a family of genes that play roles in controlling cell growth. In some breast cancers, for reasons no one understands, cancer cells have too much HER2.

Shortly after Lynberg was diagnosed, one of the first things she did was seek information and comfort online. “While I found several support groups that helped me get informed about my special form of breast cancer, I couldn’t find a site that spoke to the rest of my life – those topics that could benefit me on the road back to wellness,” she says. “I wanted to learn more about how to live the type of lifestyle I had before battling the disease. Would I still be able to enjoy my passions, like golf and travel?” Thankfully, Lynberg was able to continue pursuing those passions in one form or another, partly because her treatment included an oral therapy that she could take wherever and whenever she needed it.

Today, Lynberg’s breast cancer is in remission, but she remembers the struggles she faced at the time to figure it all out. However, she is happy to learn that the women who follow in her footsteps will not experience that same struggle. Launched this September, a new online resource is helping women and their loved ones continue to live a healthy, active, on-the-move lifestyle despite their cancer diagnosis.

HER Move (www.hermove.com) is the first ever Web-based, lifestyle program specifically for women in all stages of HER2-positive breast cancer, including the newly diagnosed, those living with advanced or metastatic disease and the long-term survivors. In addition to a unique offering of health and wellness information, there are resources that inspire women with HER2-positive breast cancer to live life to the fullest as best they can by staying on-the-move and living a healthy and active lifestyle.

Marybeth Bond, a travel expert and author of 11 travel books for women, is among the experts who have material posted on the site. “Travel has an uncanny way of taking us back to the simplicity that makes life precious again. A close friend recently told me that her first trip after diagnosis marked the beginning of hope – hope that she could live the life she had pre-cancer.”

But the key, points out Bond, is to recognize that “travel” has many definitions. “An afternoon visit to a botanical garden, a day cruise on a lake, or a walk in the woods with a loved-one can turn your attitude upside-down, change negatives into positives and pain into purpose.”

Those who have questions about intimacy, sexual connection and romance – generally not topics that are easy to discuss with your doctor, let alone their partner – can find answers courtesy of Ruth Peltason, author of the book, “I AM NOT MY BREAST CANCER.” A breast cancer survivor herself, she interviewed hundreds of women from all walks of life to get their take on the topic and shares what she learned on the site.

There’s also a section dedicated to caregivers headed up by HER2 Support Group’s (www.her2support.org) Joe Druther, whose wife, Christine, is a breast cancer survivor. “While being a caregiver can be stressful, there are many support groups made up of people like me who were unexpectedly given the role of caregiver. It can take some time to get adjusted to this new role, but know it is a crucial one – one that may be challenging at times, yet rewarding because you are, after all, helping someone you love.”

In addition to sharing resources, the site also creates a community where women can share their personal stories, anecdotes, recipes and photographs among new friends, and learn from the experiences of others. HER Move was funded and developed by GlaxoSmithKline Oncology.

Courtesy of ARAcontent

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page